Previous 10 | Next 10 |
Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022 PR Newswire NEW HAVEN, Conn. , May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage bi...
Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q1 earnings results on Monday, May 9th, before market open. The consensus EPS Estimate is -$2.27 (+23.6% Y/Y) and the consensus Revenue Estimate is $183.71M (+319.4% Y/Y). Over the last 2 years, BHVN has beaten EPS estimates 50% of...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
The European Commission (EC) granted marketing authorization to Biohaven Pharmaceutical (NYSE:BHVN) and Pfizer's (NYSE:PFE) Vydura (rimegepant) for the acute treatment of migraine with or without aura, and to prevent episodic migraine in adults who have at least four migraine attacks per...
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA ® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy underperformed during a pronounced rotation ...
Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...
Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability PR Newswire More than 25% of patients reported being severely or very severely impacted by their migraine at...
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update PR Newswire - Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives...
Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks. With new partnership...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-24 06:30:09 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for BHVN on July 24, 2024 04:48AM ET. BHVN was trading at $37.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy reco...
2024-07-24 06:00:03 ET Terence Flynn from Morgan Stanley issued a price target of $58.00 for BHVN on 2024-07-24 04:48:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $37.81. The overall price target consensus is at $4...
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...